China launches groundbreaking rules to govern frontier biomedical technologies
A landmark regulation issued by China’s State Council establishes the first comprehensive legal framework for the clinical research and clinical application of advanced biomedical technologies, including gene editing, cell therapies, and brain-computer interfaces.
The Regulations on the Administration of Clinical Research and Translational Application of New Biomedical Technologies (Order No. 818) took effect on May 1, 2026, aiming to promote innovation while ensuring safety, ethical compliance, and data integrity1. As the National Health Commission (NHC) noted in its official interpretation, it complements the Drug Administration Law and Medical Device Regulation, forming a full-chain governance system covering the entire biomedical innovation cycle.
“New biomedical technologies,” according to the regulation, refer to medical means and measures that operate on human cells or at the molecular level based on biological principles, aiming to determine health status, prevent or treat diseases, and promote health, but which have not yet been applied clinically within China. The regulations establish three fundamental prohibitions: such activities shall not harm human health, violate ethical principles, or undermine public interests and national security.
The Regulation introduces a list-based management system. The Biomedical New Technology Clinical Research Filing Guidance List includes China’s first-in-class technologies in five categories: gene therapy, cell and derivative therapy, tissue and organ therapy, microbiome-based therapy, and brain-computer interface technology. The NHC, China’s top health administration, updates the list regularly to incorporate emerging innovations and remove technologies with proven safety or ethical risks.
Regulatory paradigm shift
Prior to Order No. 818, China lacked a dedicated legal framework for frontier biomedical technologies. The regulatory system was highly fragmented: cell and gene therapies either followed the lengthy 10- to 20-year drug registration pathway administered by the National Medical Products Administration (NMPA) or operated in an unregulated gray market with no clear compliance standards. For clinical research initiation, sponsors were required to obtain prior administrative approval from health authorities, a cumbersome process that typically took 3–6 months on average and created significant delays for early-stage innovation.
The new order fundamentally reforms this system by establishing a unified full-chain governance architecture. It implements a dual-track regulatory model that separates technology-specific oversight from traditional drug and device regulation. Most notably, the prior approval requirement for clinical research has been replaced with a streamlined filing system: studies must be submitted to the NHC within 5 working days after passing academic and ethical reviews at qualified institutions.
